cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nektar Therapeutics
8 own
9 watching
Current Price
$3.08
$-0.07
(-2.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
578.9M
52-Week High
52-Week High
11.59
52-Week Low
52-Week Low
1.99
Average Volume
Average Volume
1.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.86
iconMarket Capitalization578.9M
icon52-Week High11.59
icon52-Week Low1.99
iconAverage Volume1.05M
iconDividend Yield--
iconP/E Ratio9.86
What does the Nektar Therapeutics do?
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Read More
How much money does Nektar Therapeutics make?
News & Events about Nektar Therapeutics.
Business Wire
8days ago
Glancy Prongay & Murray LLP (GPM) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors and officers possible violations of state laws. If you own Nektar Therapeutics stock, would like to learn more about these claims, or have any...
PR Newswire
1month ago
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire SAN...
Globe Newswire
1month ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential self-...
PR Newswire
1month ago
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire SAN FRANCISCO, Dec. 12, 2022 -- Unveils Trial Design for NektarPhase 2/3 Study...
PR Newswire
2 months ago
Nektar Therapeutics to Host Investor & Analyst Event on December 12th Nektar Therapeutics to Host Investor & Analyst Event on December 12th PR Newswire SAN FRANCISCO, Dec. 5, 2022 SAN FRANCISCO, Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it...
Frequently Asked Questions
Frequently Asked Questions
What is Nektar Therapeutics share price today?
plus_minus_icon
Can Indians buy Nektar Therapeutics shares?
plus_minus_icon
How can I buy Nektar Therapeutics shares from India?
plus_minus_icon
Can Fractional shares of Nektar Therapeutics be purchased?
plus_minus_icon
What are the documents required to start investing in Nektar Therapeutics stocks?
plus_minus_icon
What is today’s traded volume of Nektar Therapeutics?
plus_minus_icon
What is today’s market capitalisation of Nektar Therapeutics?
plus_minus_icon
What is the 52-Week High and Low Range of Nektar Therapeutics?
plus_minus_icon
What percentage is Nektar Therapeutics down from its 52-Week High?
plus_minus_icon
What percentage is Nektar Therapeutics up from its 52-Week Low?
plus_minus_icon
Current Price
$3.08
$-0.07
(-2.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00